InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,347.61
(
0.16%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

rkrw

Send PM Follow Ignore
Followers 45
Posts 3204
Boards Moderated 0
Alias Born 12/29/2003

rkrw

Member Level

Re: genisi post# 84494

Sunday, 10/04/2009 9:48:08 AM

Sunday, October 04, 2009 9:48:08 AM

Post# of 252302
Talecris also is facing a future threat in baxter's pivotal study for a 1/monthly, 1 injection site of IGIV. Versus the talecris injectable which is once/week with several injection sites and poor bioavailability, so higher doses needed. IGIV is Talecris's biggest product.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up